BPC-157 vs IllumiNeuro Protocol

Extensively Studied vs Limited Research
compatible Different targets; BPC-157 may complement with healing/gut-brain effects.

Molecular Data

BPC-157 IllumiNeuro Protocol
Weight 1,419.53 Da
Half-life <30 minutes
Chain 15 amino acids
Type Pentadecapeptide Fixed-ratio peptide combination

Key Benefits

BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
IllumiNeuro Protocol
01 Multi-pathway cognitive enhancement
02 Neuroprotective and neuritogenic effects
03 Anxiolytic properties from NA-Selank
04 BDNF upregulation from NA-Semax
05 Circadian/sleep support from Pinealon
06 Convenience of single injection
07 Extended-action amidate forms included

Dosing Protocols

BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
IllumiNeuro Protocol
100-500 mcg total blend per day / Once daily, preferably in the morning for cognitive benefits
Conservative cognitive support 100-200mcg total blend Once daily (morning)
Standard protocol 200-400mcg total blend Once daily
Enhanced protocol 400-500mcg total blend Once daily

Side Effects

BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
IllumiNeuro Protocol
Injection site reactions (mild)
Nasal irritation if used intranasally
Possible vivid dreams (Pinealon effect)
Mild headache initially
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
No clinical trials on four-peptide combination
Bipolar disorder or psychosis (caution with cognitive enhancers)
Pregnancy or breastfeeding
Seizure disorders (theoretical concern)

Research Evidence

BPC-157 IllumiNeuro Protocol
Status Extensively Studied Limited Research
References 6 studies 4 studies
Latest January 2025
FDA Approved No No

This comparison is for educational and research purposes only. Consult a healthcare professional before use.